Celgene is getting a pipeline confidence boost courtesy of its friends at Acceleron Pharma. Next, Celgene can help itself by raising financial guidance for the rest of the year.

On Monday night, Celgene and Acceleron said their partnered drug luspatercept met all primary and secondary endpoints in a Phase 3 clinical trial of patients with transfusion-dependent beta thalassemia. The good news was a fast follow to a similar win for luspatercept in a Phase 3 trial involving patients with another blood disease — myelodysplastic syndrome.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy